Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Form S-1/A Chardan NexTech Acquisit
-
International Media Acquisition Corp. Announces Closing of $200 Million Initial Public Offering
-
Chardan Expands Equity Research Team
-
CleanTech Acquisition Corp. Announces the Separate Trading of its Common Stock, Rights and Warrants, Commencing August 4, 2021
-
CleanTech Acquisition Corp. Announces the Separate Trading of its Common Stock, Rights and Warrants, Commencing August 4, 2021
-
Tenaya Therapeutics (TYNA) IPO Opens 30% Higher
-
Evelo Biosciences Inc (EVLO) PT Lowered to $12 at Chardan Capital Markets
-
CRISPR Therapeutics (CRSP) PT Lowered to $171 at Chardan Capital Markets
-
Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering
-
Form 3 Chardan Healthcare Acqui For: Jul 22 Filed by: RTW INVESTMENTS, LP
-
Form SC 13G Chardan Healthcare Acqui Filed by: RTW INVESTMENTS, LP
-
International Media Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering on NASDAQ
-
CleanTech Acquisition Corp. Announces Exercise of $22.5 Million Over-Allotment Option by Underwriters
-
CleanTech Acquisition Corp. Announces Exercise of $22.5 Million Over-Allotment Option by Underwriters
-
Form PRER14A Chardan Healthcare Acqui
-
A SPAC I Acquisition Corp. (ASPAU) Announces 8M Unit IPO at $10/unit
-
BiomX Inc. (PHGE) Announces $15 Million Registered Direct Offering of Common Stock, Warrants
-
BiomX Inc. Announces $15 Million Registered Direct Offering
-
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
-
Form S-1/A Chardan NexTech Acquisit
-
Seres Therapeutics (MCRB) PT Lowered to $16 at Chardan Capital Markets
-
CleanTech Acquisition Corp. Announces Closing of $150 Million Initial Public Offering
-
CleanTech Acquisition Corp. Announces Closing of $150 Million Initial Public Offering
-
Form DEFA14A Chardan Healthcare Acqui
-
Renovacor Announces the Appointment of Elizabeth White, Ph.D., as Chief Business Officer and Senior Vice President of Operations
-
Abri SPAC I, Inc (ASPAU) Announces 5M Unit IPO at $10/unit
-
IPO for SPAC CleanTech Acquisition Corp. (CLAQ) Opens at $10.02
-
CleanTech Acquisition Corp (CLAQU) Prices 15M Unit IPO at $10/unit
-
CleanTech Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering
-
CleanTech Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering
-
Form PRER14A Chardan Healthcare Acqui
-
Form S-1/A Chardan NexTech Acquisit
-
Chardan Capital Markets Starts Femasys Inc. (FEMY) at Buy
-
Form DEFA14A Chardan Healthcare Acqui
-
Chardan Names Gbola Amusa, MD, CFA Chief Scientific Officer
-
Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance
-
Tenaya Therapeutics, Inc (TNYA) Files up to $100M IPO
-
CHW Acquisition Corporation (CHWAU) Announces 10M Unit IPO at $10/unit
-
Form DEFA14A Chardan Healthcare Acqui
-
Renovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Directors
-
Intellia Therapeutics (NTLA) PT Raised to $130 at Chardan Capital Markets
-
CLEANTECH ACQUISITION CORP (CLAQU) Announces 15M Unit IPO at $10/unit
-
Pear Therapeutics to Become Public Company via Merger with Thimble Point Acquisition Corp. (THMA)
-
Pear Therapeutics to Become a Public Company and Expand its Leadership Position in Prescription Digital Therapeutics
-
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition (BCYP)
-
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerg
-
Chardan Acts as Lead Left Bookrunner in Femasys' $34.45 Million IPO
-
Femasys (FEMY) IPO Opens Flat
-
Femasys Inc. Announces Pricing of Initial Public Offering
-
Femasys Inc. Announces Pricing of Initial Public Offering

